Hepatospecific insulin analogues
AssigneeMount Sinai School of Medicine of the City University of New York
InventorPanayotis G. Katsoyannis
Life of this patent
Estimating the term…
Abstract
New insulin analogues have now been synthesized and found to be hepatospecific. These insulin analogues contain substitutions for one This invention was made with government support under grant #DK-12925 awarded by the National Institutes of Health. The government has certain rights in the invention.
Claims14
An analogue of a naturally occurring insulin having an A chain comprising amino acids A1 through A21 and a B chain comprising amino acids B1 through B30, in which analogue the A14 amino acid is substituted with an amino acid residue selected from the group consisting of tryptophan, naphtylalanine, N.sup..gamma. -dansyl-a, .gamma.-diaminobutyric acid, leucine, valine, alanine, isoleucine, proline, and methionine, said insulin analogue otherwise being sufficiently structurally similar to natural insulin so as to retain at least some therapeutically effective portion of insulin potency.
An analogue of a naturally occurring insulin having an A chain comprising amino acids A1 through A21 and a B chain comprising amino acids B1 through B30, in which analogue tryptophan is substituted in the A chain for an amino acid selected from the group consisting of the A13 amino acid, the A14 amino acid, and combinations thereof, said insulin analogue otherwide being sufficiently structurally similar to natural insulin so as to retain at least one therapeutically effective portion of insulin potency.
An insulin analogue having the formula ##STR2##
Dependencies are inferred from the claim text.